Biochemical and clinical evaluation of a new cellulose diacetate secondary filter for cascade filtration.
We have performed 24 cascade filtration treatments in 8 patients with hyperviscosity syndrome (2 cases), essential mixed cryoglobulinemia, post-hepatitic cryoglobulinemia, Sjogrens disease, rheumatoid vasculitis, Miller-Fisher syndrome and chronic dysimmune polyneuropathy. New cellulose diacetate filters were employed, giving a satisfactory performance. At 1.5 L plasma treatment, the rejection rate for macromolecular plasma components was close to 90%, whereas albumin recovery was close to 70%. Treatments were clinically effective, confirming that cascade filtration is an alternative to conventional plasma exchange in patients with IgM or immune complex mediated diseases.
D001809:Blood Viscosity; D002482:Cellulose / Q000031:analogs & derivatives*; D003449:Cryoglobulinemia / Q000628:therapy; D005374:Filtration / Q000295:instrumentation*; D006801:Humans; D010956:Plasmapheresis / Q000295:instrumentation*; D014657:Vasculitis / Q000628:therapy; D008258:Waldenstrom Macroglobulinemia / Q000628:therapy
D002482:Cellulose; C026170:cellulose diacetate